Silo Pharma Gains US Patent for Innovative PTSD Treatment, Plans SPC-15 Trial

SARASOTA, FL, Jan. 08, 2025 – Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company engaged in the development of innovative therapies and drug delivery methods for conventional and psychedelic treatments, has announced a significant advancement in its intellectual property portfolio. The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Silo's patent application numbered 17/954,864. This patent, titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females," is poised to offer enhanced legal protection for Silo's primary product, SPC-15.

Following the Notice of Allowance, Silo Pharma completed the necessary paperwork and paid the required fees, anticipating the formal issuance of the patent within the next three months. Once granted, this patent will strengthen the company's ownership and proprietary rights over SPC-15, an intranasal treatment specifically designed to address post-traumatic stress disorder (PTSD). The patent builds upon previous claims included in U.S. Patent 11,491,120, which was awarded to Silo in early 2023.

Eric Weisblum, CEO of Silo Pharma, expressed his satisfaction with this development, emphasizing its importance in expanding intellectual property protections for SPC-15 and enhancing the company's technological advantages. This patent approval is expected to play a crucial role in safeguarding Silo's innovations and supporting its strategic goals.

In addition to the patent news, Silo Pharma maintains an exclusive licensing agreement with Columbia University, which grants them the rights to develop, manufacture, and commercialize SPC-15 on a global scale. This partnership has yielded numerous issued patents and pending intellectual property applications related to SPC-15 technology.

SPC-15 is a promising serotonin 5-HT4 receptor agonist aimed at treating stress-related disorders, including PTSD and anxiety. Administered through an intranasal route, SPC-15 could potentially benefit from the FDA's expedited 505(b)(2) regulatory pathway, which may streamline the approval process. Currently, Silo Pharma is conducting preclinical studies in collaboration with Columbia University and holds exclusive rights for the global development and commercialization of SPC-15.

Silo Pharma, Inc. is a developmental stage biopharmaceutical company that focuses on creating innovative therapies for conditions that are often underserved. The company's efforts are directed towards addressing stress-induced psychiatric disorders, chronic pain issues, and central nervous system diseases. Silo is recognized for its novel approaches in both traditional and psychedelic treatment formulations, along with advanced drug delivery systems.

Among Silo's flagship programs is SPC-15, aimed at treating PTSD and anxiety disorders related to stress. Additionally, the company is developing SP-26, a time-release ketamine-loaded implant designed for alleviating fibromyalgia and chronic pain. Silo's preclinical ventures also include SPC-14, an intranasal treatment targeting Alzheimer's disease, and SPU-16, a peptide targeting multiple sclerosis (MS) within the central nervous system. Silo's research and development efforts are conducted in partnership with universities and independent research facilities.